Vaxcyte gets FDA fast track designation for PCV candidate VAX-24
Vaxcyte has secured fast track designation for VAX-24, its 24-valent pneumococcal conjugate vaccine (PCV) candidate, from the US Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) in adults aged 18 and over. The California-based clinical-stage vaccine developer said that it has also had a pre-investigational new drug (IND) meeting with […]